Buradasınız

Anasayfa » Content

Ankilozan Spondilitli Bir Hemodiyaliz Hastasında Etanersept Tedavisine Beklenmeyen Olumlu Yanıt

Unexpected Beneficial Response to Etanercept Therapy in a Hemodialysis Patient with Ankylosing Spondylitis

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2014
DOI: 
10.5262/tndt.2014.1001.13

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Erythropoietin (EPO) defi ciency is the main cause of renal anemia. However, chronic infl ammation may be one of the important causes for EPO resistance in patients with renal anemia. Inhibition of erythropoiesis by cytokines such as tumour necrosis factor alpha (TNF-α) may play an important role. Etanercept, a recombinant dimeric fusion protein consisting of a TNF-α receptor ligand-binding region linked to the Fc portion of human IgG, is approved for use in the treatment of ankylosing spondylitis. Here, we present an end-stage renal failure patient with ankylosing spondylitis treated by etanercept and observed no need for erythropoietin during etanercept treatment.
Bookmark/Search this post with
Abstract (Original Language): 
Eritropoietin (EPO) eksikliği renal aneminin başlıca nedenidir. Bununla birlikte, kronik infl amasyon renal anemili hastalarda EPO tedavisine karşı dirence yol açabilir. Tümör nekrozis faktör alfa (TNF-α) gibi sitokinlerle eritropoezin inhibisyonu önemli rol oynayabilir. Bir TNF-α blokörü olan etanersept ankilozan spondilit tedavisinde kullanılmaktadır. Biz bu raporda ankilozan spondilitli, etanersept ile tedavi edilen ve bu tedavi süresince eritropoietin tedavisine gereksinim duymayan bir son dönem böbrek yetmezlikli hastayı sunuyoruz.
FULL TEXT (PDF): 
PDF icon arastirmax-ankilozan-spondilitli-bir-hemodiyaliz-hastasinda-etanersept-tedavisine-beklenmeyen-olumlu-yanit.pdf
  • 1
63
65
  • Turkish

REFERENCES

References: 

1. Yuen D, Richardson RM, Fenton SS, McGrath-Chong ME, Chan
CT: Quotidian nocturnal hemodialysis improves cytokine profi le
and enhances erythropoietin responsiveness. ASAIO J 2005; 51(3):
236-241
2. Macdougall IC: Could anti-infl ammatory cytokine therapy improve
poor treatment outcomes in dialysis patients? Nephrol Dial
Transplant 2004; 19 Suppl 5: V73-78
3. Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G: Henoch-
Schönlein purpura after etanercept therapy for psoriasis. J Clin
Rheumatol 2006; 12(5): 249-251
4. Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA:
The pharmacokinetics of etanercept in patients with end-stage
renal disease on haemodialysis. J Pharm Pharmacol 2005; 57(11):
1407-1413
5. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J,
Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel
Ankylosing Spondylitis Study Group: Recombinant human tumor
necrosis factor receptor (etanercept) for treating ankylosing
spondylitis: A randomized, controlled trial. Arthritis Rheum 2003;
48(11): 3230-3236
6. Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of
CFU-E colony formation in uremic patients with infl ammatory
disease: Role of IFN-gamma and TNF-alpha. J Investig Med 1999;
47(5): 204-211
7. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE,
Farrand A, Troutt AB, Ledbetter JA, Deeg HJ: A role for tumour
necrosis factor-alpha, Fas and Fas-Ligand in marrow failure
associated with myelodysplastic syndrome. Br J Haematol 1998;
103(1): 176-188

Thank you for copying data from http://www.arastirmax.com